COLUMBIA, Md.--(BUSINESS WIRE)--Celsion Corporation, a leading oncology drug development company, announced today that the first patient in China has been enrolled and treated as part of Celsion’s global Phase III ThermoDox HEAT trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Following recent regulatory approvals in China, Malaysia and the Philippines, the study is now recruiting patients in ten of eleven planned countries, with the majority of clinical sites located in the Asia Pacific region where HCC is most prevalent.
